Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Curis, Inc. (CRIS), Appoints Mani Mohindru, Ph.D., As Vice President Of Corporate Strategy And Investor Relations

|Includes: Curis, Inc. (CRIS)

Oncology based company, Curis, Inc. (NASDAQ:CRIS), announced earlier today the appointment of Dr. Mani Mohindru as Vice President of Corporate Strategy and Investor Relations. Dr. Mohindru, recruited for her expertise and experience supporting development and corporate strategy will direct product strategy, corporate development, investor relations and corporate communications. Curis, Inc. currently seeks to both develop and commercialize next generation targeted drug candidates for cancer treatment purposes.

"Dr. Mohindru brings to Curis a strong and unique understanding of cancer drug markets and development strategies due to her wealth of experience in the analysis of the biotechnology sector," stated Mike Gray, Curis Chief Business and Financial Officer. "Mani's diverse set of industry knowledge, professional networks, and experience will be an important addition to our team as we seek to advance our pipeline of novel oncology drug candidates for patients and work to create long-term shareholder value."

Previously Dr. Mohindru spent several years as a Wall Street equity research analyst. Covering the biotechnology sector, she has held prominent positions including analyst roles at ThinkEquity LLC, Credit Suisse Securities and UBS Securities. Prior to that Dr. Mohindru sat as a healthcare industry consultant for Axon Healthcare Partners and SAI Healthcare, acquired by IMS Health, and additionally as a Managing Director in healthcare investment banking for Capstone Investments. Dr. Mohindru currently holds a Ph.D. in Neurosciences from Northwestern University. She also holds a B.Sc. in Human Biology and a M.S. in Biotechnology from the All India Institute of Medical Sciences, New Delhi, India.

"I am excited to join the Curis team as the company continues to advance its proprietary cancer drug candidates CUDC-907 and CUDC-427 in clinical trials, and to work with our partners Genentech and Debiopharm on Erivedge(NYSE:R) and Debio 0932," commented Dr. Mohindru. "Given these achievements, I believe Curis is well-positioned to leverage its expertise in developing cancer therapeutics and become a leading innovator of targeted oncology drug candidates."

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net